Table 2.
Presence of MICA antibodies and their effect on allograft outcome in solid organ transplantation.
| Organ | Detection time | Year | Number of patients | Transplant (DD/LD) | Follow-up (duration) | Reference | Outcome |
|---|---|---|---|---|---|---|---|
| Kidney | Pre-tx | 2002 | 139 | DD | 3 months | Sumitran-Holgersson et al. (40) | ↑AMR |
| 2007 | 1,910 | DD | 1 year | Zou et al. (43) | ↑AMR, ↓GS | ||
| 2010 | 425 | NS | 1, 5, and 10 years | Lemy et al. (44) | ↔ | ||
| 2012 | 40 | LD | 1 year | Solgi et al. (45) | ↔ | ||
| 2013 | 727 | DD + LD | 3, 6, 12, and 24 months | Sánchez-Zapardiel et al. (46) | ↑AMR | ||
| Post-tx | 2005 | 145 | DD + LD | 10 years | Mizutani et al. (41) | ↓GS | |
| 2007 | 185 | LD | Panigrahi et al. (47) | ↑AMR | |||
| 2007 | 1,921 | DD + LD | 4 years | Terasaki et al. (48) | ↓GS | ||
| 2009 | 284 | DD | 3 years | Suarez-Alvarez et al. (49) | ↑AMR | ||
| 2011 | 442 | DD + LD | 5.9 years (mean) | Cox et al. (50) | ↑CR | ||
| 2012 | 779 | DD + LD | 4 years | Lemy et al. (51) | ↔ | ||
| 2012 | 147 | DD + LD | 6 months | Seyhun et al. (52) | ↔ | ||
| Heart | Pre and post-tx | 2007 | 44 | DD | 1 year | Suarez-Alvarez et al. (53) | ↑AMR |
| Pre-tx | 2009 | 491 | DD | 1 and 5 years | Smith et al. (54) | ↔AMR/CAV ↑GS | |
| Pre-tx | 2010 | 63 | DD | 6 months | Pavlova et al. (55) | ↔ | |
| Post-tx | 2010 | 95 | DD | 1.8 and 8.9 years (mean) | Nath et al. (56) | ↑AMR, ↑CAV | |
| Post-tx | 2011 | 168 | DD | 2 years (median) | Zhang et al. (57) | ↑AMR | |
| 2015 | 05 | Animal experiments (rat-to-mouse cardiac transplantation model) | Yu et al. (58) | ↑AR | |||
| Liver | 2008 | 84 | NS | 2 years | Uzunel et al. (59) | ↔ | |
| 2013 | 123 | NS | 7 years | Ciszek et al. (60) | ↔ |
MICA, major histocompatibility complex class I chain-related molecule A; AT1R, angiotensin II type 1 receptor; AECA, anti-endothelial cell antibody; Col V, collagen V; KA1T, k-α1 tubulin; LSECs, liver sinusoidal endothelial cells; AMR, antibody-mediated rejection; GS, graft survival; AVR, acute vascular rejection; CAV, cardiac allograft vasculopathy; BOS, bronchiolitis obliterans syndrome; DD, deceased donor; LD, live donor; NS, not specified; AR, acute rejection; ↔, no adverse effect.